株式会社グローバルインフォメーション
TEL: 044-952-0102
市場調査レポート

遺伝子治療の世界市場(タイプ・用途別):産業展望、包括的分析、将来予測

Gene Therapy Market by Type (Somatic Cell Gene Therapy and Germ Cell Gene Therapy) and by Application (Genetic Disorders, Cancer, Cardiovascular Disease, and Others): Global Industry Perspective, Comprehensive Analysis, and Forecast, 2017-2024

発行 Zion Market Research 商品コード 843100
出版日 ページ情報 英文 110 Pages
納期: 2-3営業日
価格
本日の銀行送金レート: 1USD=107.15円で換算しております。
Back to Top
遺伝子治療の世界市場(タイプ・用途別):産業展望、包括的分析、将来予測 Gene Therapy Market by Type (Somatic Cell Gene Therapy and Germ Cell Gene Therapy) and by Application (Genetic Disorders, Cancer, Cardiovascular Disease, and Others): Global Industry Perspective, Comprehensive Analysis, and Forecast, 2017-2024
出版日: 2019年01月15日 ページ情報: 英文 110 Pages
概要

当レポートでは、世界の遺伝子治療市場を調査し、市場および産業の概要、タイプ・用途・地域別の市場規模の推移と予測、市場の成長要因および阻害要因の分析、市場機会、競合情勢、主要企業のプロファイルなど、包括的な情報を提供しています。

第1章 イントロダクション

  • レポート概要と範囲
  • 調査範囲
  • 調査手法

第2章 エグゼクティブサマリー

  • 市場規模の推移と予測(金額ベース)
  • 市場スナップショット

第3章 産業力学

  • イントロダクション
  • 成長要因
  • 阻害要因
  • 市場機会
  • ファイブフォース分析
  • 市場魅力分析:セグメント別

第4章 競合環境

  • 市場シェアの分析
  • 戦略動向
    • 合併・買収
    • 新材料の登場
    • 合意・パートナーシップ・コラボレーション・合弁事業
    • 研究開発・事業拡大

第5章 遺伝子治療の世界市場:タイプ別

  • 市場概要
  • 生殖細胞遺伝子治療
  • 体細胞遺伝子治療

第6章 遺伝子治療の世界市場:用途別

  • 市場概要
  • 遺伝子疾患
  • 心血管疾患
  • その他

第7章 遺伝子治療の世界市場:地域別

  • 市場概要
  • 北米
  • 欧州
  • アジア太平洋地域
  • ラテンアメリカ
  • 中東・アフリカ

第8章 企業プロファイル

  • UniQure N.V
  • Spark Therapeutics LLC
  • Bluebird Bio
  • Juno Therapeutics
  • GlaxoSmithKline
  • Celgene Corporation
  • Shire Plc
  • Sangamo Biospciences
目次

The report covers a forecast and an analysis of the gene therapy market on a global and regional level. The study provides historical data from 2015 to 2017 along with a forecast from 2018 to 2024 based on revenue (USD Million). The study includes drivers and restraints of the gene therapy market along with the impact they have on the demand over the forecast period. Additionally, the report includes the study of opportunities available in the gene therapy market on a global and regional level.

In order to give the users of this report a comprehensive view of the gene therapy market, we have included a competitive landscape and an analysis of Porters Five Forces model for the market. The study encompasses a market attractiveness analysis, wherein all the segments are benchmarked based on their market size, growth rate, and general attractiveness.

The report provides company market share analysis to give a broader overview of the key market players. In addition, the report also covers key strategic developments of the market including acquisitions mergers, new product launch, agreements, partnerships, collaborations joint ventures, research development, and regional expansion of major participants involved in the market on a global and regional basis.

The study provides a decisive view of the gene therapy market by segmenting the market based on type, application, and region. All the segments have been analyzed based on present and future trends and the market is estimated from 2018 to 2024. Based on the type, the gene therapy market is bifurcated into somatic cell gene therapy and germ cell gene therapy. Based on application, the gene therapy market is classified into genetic disorders, cancer, cardiovascular diseases, and others.

The regional segmentation includes the current and forecast demand for North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa with its further divided into major countries including the U.S., Canada, Germany, France, UK, China, Japan, India, and Brazil.

Some key players of the gene therapy market include UniQure N.V, Spark Therapeutics LLC, Bluebird Bio, Juno Therapeutics, GlaxoSmithKline, Celgene Corporation, Shire Plc, Sangamo Biosciences, Dimension Therapeutics, Voyager Therapeutics, Human Stem Cell Institute, Bristol Myers Squibb, and Chiesi Farmaceutici S.p.A., among others.

This report segments the global gene therapy market into:

Global Gene Therapy Market: By Type

  • Somatic Cell Gene Therapy
  • Germ Cell Gene Therapy

Global Gene Therapy Market: By Application

  • Genetic Disorders
  • Cancer
  • Cardiovascular Disease
  • Others

Global Gene Therapy Market: By Region

  • North America
  • The U.S.
  • Europe
  • UK
  • France
  • Germany
  • Asia Pacific
  • China
  • Japan
  • India
  • Latin America
  • Brazil
  • Middle East and Africa

Table Of Contents

Chapter 1. Introduction

  • 1.1. Report description and scope
  • 1.2. Research scope
  • 1.3. Research methodology
    • 1.3.1. Market research process
    • 1.3.2. Market research methodology

Chapter 2. Executive Summary

  • 2.1. Global gene therapy market, 2017 - 2024 (USD Million)
  • 2.2. Global gene therapy market: Snapshot

Chapter 3. Gene Therapy Market - Industry Dynamics

  • 3.1. Introduction
  • 3.2. Market drivers
    • 3.2.1. Global gene therapy market drivers: Impact analysis
    • 3.2.2. The increasing prevalence of genetic disorders and other lifestyle-related life-threatening diseases across the globe
    • 3.2.3. Rising need for gene therapy based targeted treatment
  • 3.3. Market Restraints
    • 3.3.1. Global Gene therapy market restraints: Impact analysis
    • 3.3.2. Need for an individual case-by-case approach
  • 3.4. Opportunities
    • 3.4.1. Increasing adoption of personalized medicines
  • 3.5. Porter's five forces analysis
    • 3.5.1. Bargaining power of suppliers
    • 3.5.2. Bargaining power of buyers
    • 3.5.3. The threat from new entrants
    • 3.5.4. The threat from new substitutes
    • 3.5.5. Degree of competition
  • 3.6. Market attractiveness analysis
    • 3.6.1. Market attractiveness analysis, by type
    • 3.6.2. Market attractiveness analysis, by application
    • 3.6.3. Market attractiveness analysis, by region

Chapter 4. Global Gene Therapy Market - Competitive Landscape

  • 4.1. Company Market Share Analysis
    • 4.1.1. Global gene therapy market: company market share, 2017
  • 4.2. Strategic Development
    • 4.2.1. Acquisitions & Mergers
    • 4.2.2. New Product Launch
    • 4.2.3. Agreements, Partnerships, Collaborations, and Joint Ventures
    • 4.2.4. Research and Development and Regional Expansion

Chapter 5. Global Gene Therapy Market - Type Analysis

  • 5.1. Global gene therapy market: Type overview
    • 5.1.1. Global gene therapy market revenue share, by Type, 2017 and 2024
  • 5.2. Somatic cell gene therapy
    • 5.2.1. Global gene therapy market for Somatic cell gene therapy, 2017 - 2024 (USD Million)
  • 5.3. Germ cell gene therapy
    • 5.3.1. Global gene therapy market for Germ Cell Gene Therapy, 2017 - 2024 (USD Million)

Chapter 6. Global Gene Therapy Market - Application Analysis

  • 6.1. Global gene therapy market: Application overview
    • 6.1.1. Global gene therapy market revenue share, by Application, 2017 and 2024
  • 6.2. Genetic Disorders
    • 6.2.1. Global gene therapy market for genetic disorders, 2017 - 2024 (USD Million)
  • 6.3. Cancer
    • 6.3.1. Global gene therapy market for Cancer, 2017 - 2024 (USD Million)
  • 6.4. Cardiovascular Disease
    • 6.4.1. Global gene therapy market for Cardiovascular Disease, 2017 - 2024 (USD Million)
  • 6.5. Other Diseases
    • 6.5.1. Global gene therapy market for other diseases, 2017 - 2024 (USD Million)

Chapter 7. Global Gene Therapy Market - Regional Analysis

  • 7.1. Global gene therapy market: Regional overview
    • 7.1.1. Global gene therapy market revenue share, by region, 2017 and 2024
  • 7.2. North America
    • 7.2.1. North America gene therapy market revenue, by type, 2017 - 2024 (USD Million)
    • 7.2.2. North America gene therapy market revenue, by application, 2017 - 2024 (USD Million)
    • 7.2.3. The U.S.
      • 7.2.3.1. The U.S. gene therapy market revenue, by type, 2017 - 2024 (USD Million)
      • 7.2.3.2. The U.S. gene therapy market revenue, by application, 2017 - 2024 (USD Million)
    • 7.2.4. Canada
      • 7.2.4.1. Canada gene therapy market revenue, by type, 2017 - 2024 (USD Million)
      • 7.2.4.2. Canada gene therapy market revenue, by application, 2017 - 2024 (USD Million)
    • 7.2.5. Rest of North America
      • 7.2.5.1. Rest of North America gene therapy market revenue, by type, 2017 - 2024 (USD Million)
      • 7.2.5.2. Rest of North America gene therapy market revenue, by application, 2017 - 2024 (USD Million)
  • 7.3. Europe
    • 7.3.1. Europe gene therapy market revenue, by type, 2017 - 2024 (USD Million)
    • 7.3.2. Europe gene therapy market revenue, by application, 2017 - 2024 (USD Million)
    • 7.3.3. U.K.
      • 7.3.3.1. U.K. gene therapy market revenue, by type, 2017 - 2024 (USD Million)
      • 7.3.3.2. U.K. gene therapy market revenue, by application, 2017 - 2024 (USD Million)
    • 7.3.4. Germany
      • 7.3.4.1. Germany gene therapy market revenue, by type, 2017 - 2024 (USD Million)
      • 7.3.4.2. Germany gene therapy market revenue, by application, 2017 - 2024 (USD Million)
    • 7.3.5. France
      • 7.3.5.1. France gene therapy market revenue, by type, 2017 - 2024 (USD Million)
      • 7.3.5.2. France gene therapy market revenue, by application, 2017 - 2024 (USD Million)
    • 7.3.6. Italy
      • 7.3.6.1. Italy gene therapy market revenue, by type, 2017 - 2024 (USD Million)
      • 7.3.6.2. Italy gene therapy market revenue, by application, 2017 - 2024 (USD Million)
    • 7.3.7. Spain
      • 7.3.7.1. Spain gene therapy market revenue, by type, 2017 - 2024 (USD Million)
      • 7.3.7.2. Spain gene therapy market revenue, by application, 2017 - 2024 (USD Million)
    • 7.3.8. Russia
      • 7.3.8.1. Russia gene therapy market revenue, by type, 2017 - 2024 (USD Million)
      • 7.3.8.2. Russia gene therapy market revenue, by application, 2017 - 2024 (USD Million)
    • 7.3.9. Rest of Europe
      • 7.3.9.1. Rest of Europe gene therapy market revenue, by type, 2017 - 2024 (USD Million)
      • 7.3.9.2. Rest of Europe gene therapy market revenue, by application, 2017 - 2024 (USD Million)
  • 7.4. Asia Pacific
    • 7.4.1. Asia Pacific gene therapy market revenue, by type, 2017 - 2024 (USD Million)
    • 7.4.2. Asia Pacific gene therapy market revenue, by application, 2017 - 2024 (USD Million)
    • 7.4.3. China
      • 7.4.3.1. China gene therapy market revenue, by type, 2017 - 2024 (USD Million)
      • 7.4.3.2. China gene therapy market revenue, by application, 2017 - 2024 (USD Million)
    • 7.4.4. Japan
      • 7.4.4.1. Japan gene therapy market revenue, by type, 2017 - 2024 (USD Million)
      • 7.4.4.2. Japan gene therapy market revenue, by application, 2017 - 2024 (USD Million)
    • 7.4.5. India
      • 7.4.5.1. India gene therapy market revenue, by type, 2017 - 2024 (USD Million)
      • 7.4.5.2. India gene therapy market revenue, by application, 2017 - 2024 (USD Million)
    • 7.4.6. Australia
      • 7.4.6.1. Australia gene therapy market revenue, by type, 2017 - 2024 (USD Million)
      • 7.4.6.2. Australia gene therapy market revenue, by application, 2017 - 2024 (USD Million)
    • 7.4.7. Rest of Asia Pacific
      • 7.4.7.1. Rest of Asia Pacific gene therapy market revenue, by type, 2017 - 2024 (USD Million)
      • 7.4.7.2. Rest of Asia Pacific gene therapy market revenue, by application, 2017 - 2024 (USD Million)
  • 7.5. Latin America
    • 7.5.1. Latin America gene therapy market revenue, by type, 2017 - 2024(USD Million)
    • 7.5.2. Latin America gene therapy market revenue, by application, 2017 - 2024(USD Million)
    • 7.5.3. Brazil
      • 7.5.3.1. Brazil gene therapy market revenue, by type, 2017 - 2024 (USD Million)
      • 7.5.3.2. Brazil gene therapy market revenue, by application, 2017 - 2024 (USD Million)
    • 7.5.4. Mexico
      • 7.5.4.1. Mexico gene therapy market revenue, by type, 2017 - 2024 (USD Million)
      • 7.5.4.2. Mexico gene therapy market revenue, by application, 2017 - 2024 (USD Million)
    • 7.5.5. Argentina
      • 7.5.5.1. Argentina gene therapy market revenue, by type, 2017 - 2024 (USD Million)
      • 7.5.5.2. Argentina gene therapy market revenue, by application, 2017 - 2024 (USD Million)
    • 7.5.6. Rest of Latin America
      • 7.5.6.1. Rest of Latin America gene therapy market revenue, by type, 2017 - 2024 (USD Million)
      • 7.5.6.2. Rest of Latin America gene therapy market revenue, by application, 2017 - 2024 (USD Million)
  • 7.6. The Middle East and Africa
    • 7.6.1. The Middle East and Africa gene therapy market revenue, by type, 2017 - 2024 (USD Million)
    • 7.6.2. The Middle East and Africa gene therapy market revenue, by application, 2017 - 2024 (USD Million)
    • 7.6.3. Saudi Arabia
      • 7.6.3.1. Saudi Arabia gene therapy market revenue, by type, 2017 - 2024 (USD Million)
      • 7.6.3.2. Saudi Arabia gene therapy market revenue, by application, 2017 - 2024 (USD Million)
    • 7.6.4. UAE
      • 7.6.4.1. UAE gene therapy market revenue, by type, 2017 - 2024 (USD Million)
      • 7.6.4.2. UAE gene therapy market revenue, by application, 2017 - 2024 (USD Million)
    • 7.6.5. South Africa
      • 7.6.5.1. South Africa gene therapy market revenue, by type, 2017 - 2024 (USD Million)
      • 7.6.5.2. South Africa gene therapy market revenue, by application, 2017 - 2024 (USD Million)
    • 7.6.6. Qatar
      • 7.6.6.1. Qatar gene therapy market revenue, by type, 2017 - 2024 (USD Million)
      • 7.6.6.2. Qatar gene therapy market revenue, by application, 2017 - 2024 (USD Million)
    • 7.6.7. Rest of the Middle East and Africa
      • 7.6.7.1. Rest of the Middle East and Africa gene therapy market revenue, by type, 2017 - 2024 (USD Million)
      • 7.6.7.2. Rest of the Middle East and Africa gene therapy market revenue, by application, 2017 - 2024 (USD Million)

Chapter 8. Company Profile

  • 8.1. UniQure N.V
    • 8.1.1. Overview
    • 8.1.2. Financials
    • 8.1.3. Therapy portfolio
    • 8.1.4. Business strategy
    • 8.1.5. Recent developments
  • 8.2. Spark Therapeutics LLC
    • 8.2.1. Overview
    • 8.2.2. Financials
    • 8.2.3. Therapy portfolio
    • 8.2.4. Business strategy
    • 8.2.5. Recent developments
  • 8.3. Bluebird Bio
    • 8.3.1. Overview
    • 8.3.2. Financials
    • 8.3.3. Therapy portfolio
    • 8.3.4. Business strategy
    • 8.3.5. Recent developments
  • 8.4. Juno Therapeutics
    • 8.4.1. Overview
    • 8.4.2. Financials
    • 8.4.3. Therapy portfolio
    • 8.4.4. Business strategy
    • 8.4.5. Recent developments
  • 8.5. GlaxoSmithKline
    • 8.5.1. Overview
    • 8.5.2. Financials
    • 8.5.3. Therapy portfolio
    • 8.5.4. Business strategy
    • 8.5.5. Recent developments
  • 8.6. Celgene Corporation
    • 8.6.1. Overview
    • 8.6.2. Financials
    • 8.6.3. Therapy portfolio
    • 8.6.4. Business strategy
    • 8.6.5. Recent developments
  • 8.7. Shire Plc
    • 8.7.1. Overview
    • 8.7.2. Financials
    • 8.7.3. Therapy portfolio
    • 8.7.4. Business strategy
    • 8.7.5. Recent developments
  • 8.8. Sangamo Biosciences
    • 8.8.1. Overview
    • 8.8.2. Financials
    • 8.8.3. Therapy portfolio
    • 8.8.4. Business strategy
    • 8.8.5. Recent developments
Back to Top